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Abstract 
Introduction: Meteorin-like (Metrnl), also known as subfatin, is a recently discovered adipokine 
with a favourable effect on insulin sensitivity. Studies have shown lower Metrnl levels in obese 
patients. However, data on its circulating levels in type 2 diabetes mellitus (T2DM) patients are 
contradictory. This study aims to evaluate serum Metrnl levels in T2DM patients and determine 
the relationship between serum Metrnl levels and insulin resistance in these patients. 
Material and methods: This cross-sectional study was conducted among 150 participants. The 
study was carried out between June 2019 and December 2019 at the internal medicine outpatient 
clinic of a tertiary university hospital. The participants were divided into three groups: group 1 
(control group, n = 50), group 2 (newly diagnosed T2DM, n = 50), and group 3 (long-standing 
diagnosed T2DM, n = 50). An enzyme-linked immunosorbent assay (ELISA) was used to measure 
the serum levels of Subfatin (Metrnl), and the correlations of Metrnl level with anthropometric 
parameters, HOMA index, and biochemical measurements were assessed. 
Results: There was no statistically significant difference between the gender (p = 0.468) and age 
(p = 0.067) characteristics of the three groups. The Metrnl (subfatin) levels of the participants were 
as follows: control group – 20.05 (1.56–103.78); newly diagnosed T2DM group – 2.62 (1.25–
103.78); and long-standing diagnosed T2DM group – 2.01 (0.80–19.84) pg/mL. The Metrnl 
(subfatin) levels of the participants in the control group were higher than in the participants in the 
newly diagnosed T2DM and long-standing diagnosed T2DM groups (p < 0.001). Subfatin 
demonstrated a negative correlation with insulin and HOMA-IR in the control group and long-
standing diagnosed T2DM group. 
Conclusions: The subfatin level was found to be higher in the healthy control group than in both 
diabetic patient groups. Subfatin level showed negative correlation with both insulin level and 
HOMA index. There was a relationship between subfatin and insulin resistance. Low levels of 
subfatin in the diabetic patient groups may play a role in the pathogenesis of T2DM by increasing 
insulin resistance. 
Key words: subfatin/meteorin-like; type 2 diabetes mellitus; insulin resistance; newly diagnosed 
T2DM 
 
Introduction 
Diabetes mellitus (DM) is a disease characterised by vascular and neuropathic complications, in 
which carbohydrates, lipids, and proteins cannot be metabolised optimally due to insulin 
deficiency or problems related to insulin [1].  
Subfatin, also known as Metrnl, is a recently discovered adipokine. It is secreted by white adipose 
tissue and skeletal muscles [2–5]. Findings have shown that subfatin is secreted at higher 
concentrations from white and brown adipose tissues during exposure to cold and that it induces 
thermogenesis-associated genes [5]. Subfatin increases anti-inflammatory cytokines by promoting 
interleukin 4 (IL-4) expression. Moreover, there is some evidence suggesting that Metrnl has 
favourable effects on insulin sensitivity [4–6]. Subfatin (meteorin-like) controls insulin sensitivity 
via local autocrine/paracrine effects on the peroxisome proliferator-activated receptor-gamma 
(PPAR-γ) pathway [7]. The subfatin gene is located on chromosome 11qE2 in mice and on 
chromosome 17q25.3 in humans [3–5]. The subfatin protein is produced in white adipose tissues 
and skeletal muscles [3, 8] and consists of 266 amino acids, with a molecular weight of 
approximately 30 kDa [8]. Mouse and human subfatin genes have 77% sequence similarity [5]. 
Adipocyte-induced insulin resistance develops in the absence or insufficiency of subfatin [7]. 
Serum subfatin levels in type 2 diabetes patients are significantly reduced, have a negative 
correlation with glucose levels, and contribute to the worsening of glucose tolerance [9, 10]. In 
two other studies, subfatin levels were reported to increase in patients with prediabetes and type 2 
diabetes compared to control patients [11, 12]. Subfatin induces phosphorylation in the adipocyte 
tissue and increases insulin sensitivity, and its deficiency was found to cause insulin resistance in 
adipocyte tissue. Meanwhile, data on its circulating levels in type 2 diabetes mellitus (T2DM) 
patients are inconsistent [13, 3]. Subfatin is a recently discovered adipokine with a favourable 
effect on insulin sensitivity and studies have shown lower levels in obese patients. However, there 
are scarce and conflicting data with regard to type 2 diabetes mellitus (T2DM), and more 
comprehensive studies are needed. In this study, we aimed to determine whether or not subfatin 
levels could serve as a useful marker for insulin resistance in diabetic patients. 
 
Material and methods 
This cross-sectional study was conducted in the internal medicine outpatient clinic of a tertiary 
university hospital between June 2019 and December 2019. Ethical approval was obtained from 
the Ethics Committee of Non-Interventional Research of Firat University (22.11.2018/14). Those 
who met the inclusion criteria were included in the study, and written consent form was obtained 
from all participants. 
 
Patients and control subjects 
This observational study included 150 participants. Three groups were studied that included a 
group of newly diagnosed T2DM patients who were not on medical treatment (group 2) (n = 50), 
a group with long-standing diagnosed type 2 diabetes mellitus who were on medical treatment 
(group 3) (T2DM) (n = 50), and control group of healthy participants (group 1) (n = 50). The newly 
diagnosed T2DM group were identified as patients who had been T2DM diagnosed in the 
preceding three months and had not yet had drug treatment for diabetes. The long-standing T2DM 
group were defined as patients who had been diagnosed with T2DM for at least five years and had 
been on drug medication for diabetes. The long-standing T2DM group was selected among 
patients who did not use insulin. All patients in the long-standing T2DM group were selected from 
patients using metformin and gliclazide for diabetes treatment. 
The study inclusion criteria were as follows: (1) having T2DM diagnosis according to 1999 
World Health Organisation diagnostic and classification criteria; (2) a glycosylated haemoglobin 
(HbA1c) value between 6.0 and 13.0%; and (3) being over 30 years old.  
The exclusion criteria were as follows: (1) having type 1 DM diagnosis; (2) patients 
receiving different treatment protocols other than inclusion criteria; (3) having chronic 
hypertension disease; (4) having congenital anomaly, liver disease, chronic renal disease, acute 
infection, or hypothyroidism; (5) having malignancy; (6) having psychiatric and neurological 
diseases that affect cognitive functions. 
 
Data collection  
Demographic and biochemical parameters of the participants were questioned in the study. Age, 
gender, duration of T2DM, and drugs used by the participants were recorded in the questionnaire 
form. The anthropometric measurements of the participants (height, weight, and waist and hip 
circumference) were measured by the same researcher. The standing height of patients was 
measured with a linear height scale with sensitivity of 0.1 cm, and weight was measured in 
lightweight clothing to the nearest 0.1 kg with a sensitive digital scale. The waist circumference 
was measured at minimal inspiration to the nearest 0.1 cm, midway between the last rib and the 
iliac crest. Hip circumferences were measured at the level of the anterior superior iliac spine, where 
this could be felt, otherwise at the broadest circumference below the waist. Body mass index (BMI) 
was calculated by dividing body weight by the square of the height [kg/m2]. The blood pressure of 
all participants was measured with an aneroid sphygmomanometer from both arms after a rest 
period of at least 15 minutes then the mean blood pressure was recorded. 
 
Collection and storage of biological samples 
After at least 10 hours of overnight fasting, a sample of fasting venous blood was collected, and 
the serum was used for the measurement of fasting blood glucose (FBG), fasting insulin, total 
cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine by using an automatic 
biochemical analyser (FUJI DRI-CHEM 4000i, Fuji, Japan). Glycated haemoglobin (HbA1c) 
concentration was measured by high-performance liquid chromatography (HPLC) using a 
VARIANT™ II TURBO (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Serum levels of 
insulin were determined using UniCel DxI 800 Access Immunoassay System (Beckman Coulter, 
Inc., Brea, CA, USA). Fasting glucose and fasting insulin levels were then used to estimate insulin 
resistant state and β-cell function, as follows:  
HOMA-IR [mg/dL] = [fasting insulin (/mL) × Fasting glucose (mg/dL) / 405] [14]. 
Blood sample was collected into EDTA tubes for haemoglobin measurement. Haemoglobin 
measurements with the automated analyser in the laboratory (Coulter Hmx Haematology Flow 
Cytometer, Beckman Inc., CA, USA) were performed in accordance with our standard clinical 
practice 
 
Measurement of serum subfatin (Metrnl) levels 
Blood samples were collected into aprotinin tubes were stored at –20ºC after centrifugation until 
they were analysed. Serum subfatin (Metrnl) levels were measured using enzyme-linked 
immunosorbent assay (ELISA) kits (Code: 201-12-9252) (Bioassay Technology Laboratory 
Shanghai, China). The intra-assay coefficient of variation values of ELISA kits were less than 8%, 
while the inter-assay coefficient of variation values were less than 10%. The measuring range 
(standard curve) of the subfatin kit was 0.05−15 ng/mL, and the minimum measurable level 
(sensitivity) was 0.023 ng/mL.  
 
 
Statistical analyses 
Statistical analysis of the data was performed by IBM SPSS 22 statistics package software. The 
Shapiro-Wilk test was used to determine whether the data showed normal distribution. Descriptive 
statistics of the data were expressed as mean ± standard deviation for variables with normal 
distribution in continuous data, [median (minimum: maximum) for non-normal distribution 
variables, and frequency for categorical variables as percentage (n (%)]. Categorical variables were 
compared using chi-squared tests. In the comparison of more than two independent groups, one-
way ANOVA and LSD test for post hoc testing were used for normally distributed continuous data, 
and  the Kruskal-Wallis test and Dunn tests were used for post hoc testing for non-normally 
distributed continuous data. For the relationship between two sets of continuous data, Pearson 
correlation analysis was used for normally distributed continuous data and Spearman’s correlation 
analysis was used for non-normally distributed variables. The significance level was α = 0.05. 
 
Results 
A total of 150 participants included in the study were divided into three groups. There was no 
statistically significant difference in gender (p = 0.468) and age (p = 0.067) characteristics between 
the three groups. Compared with the control group, the group with newly diagnosed T2DM and 
the long-standing diagnosed T2DM group had significantly higher BMI (p < 0.001), FBG (p < 
0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-C (p < 0.001), and triglyceride (p < 
0.001) levels. Compared with the newly diagnosed T2DM and long-standing diagnosed T2DM 
groups, the control group had significantly higher Metrnl (subfatin) levels (p < 0.001). The details 
of the anthropometric and biochemical data of the study population are given in Table 1. 
 
Table 1. Anthropometric and metabolic parameters of the studied population 
Variables Group 1 
(n = 50) 
Group 2 
(n = 50) 
Group 3 
(n = 50) 
p* 
value  
p** value 
 
Age (years) 
 
49.94 ± 12.511 
 
52.42 ± 
12.572 
 
55.38 ± 9.493 
 
0.067 
1–2: 0.288 
1–3: 0.051 
2–3: 0.205 
Gender       
Female n (%)* 26 (29.5) 30 (34.1) 32 (36.4) 0.468  
Male n (%)* 25 (38.7) 20 (32.3) 18 (29.0)   
DM duration 
(mean ± SD) 
1.78 ± 0.74a 8.22 ± 1.92a 0.00 ± 0.0   
 
BMI [kg/m2] 
 
25.37 ± 3.361 
 
29.47± 4.352 
 
30.84 ± 5.183 
 
< 0.001 
1–2: < 
0.001 
1–3: < 
0.001 
2–3: 
0.120 
 
SBP [mmHg] 
 
120.50 ± 10.061 
 
 
121.80 ± 
11.682 
 
120.40 ± 
12.653 
 
 
0.795 
1–2: 
0.573 
1–3: 
0.975 
2–3: 
0.544 
 
DBP [mmHg] 
 
74.50 ± 6.561 
 
 
73.70 ± 8.622 
 
74.10 ± 7.933 
 
0.876 
1–2: 
0.607 
1–3: 
0.797 
2–3: 
0.797 
FBG [mg/dL] 91.001 
(61.0–110.0) 
 
1272 
(88.0–407.0) 
157.503 
(82.0–352.0) 
 
< 0.001 
1–2: < 
0.001 
1–3: < 
0.001 
2–3: 
0.860 
Insulin [uU/mL] 6.801 
(2.90–22.80) 
 
13.302 
(3.93–
181.00) 
9.453 
(2.00–47.30) 
 
< 0.001 
1–2: < 
0.001 
1–3: 1.01 
2–3: 
0.001 
HOMA-IR 
(index) 
1.411 
(0.60–5.12) 
4.602 
(0.98-59.00) 
3.213 
(0.86–33.80) 
 
< 0.001 
1–2: < 
0.001 
1–3: 
0.214 
2–3: 
0.003 
 
HbA1c (%) 
 
5.24 ± 0.29 
 
8.09 ± 2.35 
 
8.31 ± 2.25 
 
< 0.001 
1–2: < 
0.001 
1–3: < 
0.001 
2–3: 
0.565 
 
Total cholesterol 
[mg/dL] 
 
172.50 ± 29.991 
 
 
195.64 ± 
39.192 
 
206.26 ± 
34.073 
 
< 0.001 
1–2: < 
0.001 
1–3: 
0.001 
2–3: 
0.127 
 
LDL-C [mg/dL] 
 
100.58 ± 25.511  
 
126.68 ± 
38.062 
 
131.88 ± 
32.433 
 
< 0.001 
1–2: < 
0.001 
1–3: < 
0.001 
2–3: 
0.424 
 
HDL-C [mg/dL] 
 
37.82 ± .74 
 
36.30 ± 4.76 
  
 
36.74 ± 3.17 
 
0.193 
1–2: 
0.182 
1–3: 
0.420 
2–3: 
0.865 
Triglyceride 
[mg/dL] 
83.501 
(41.0–225.0) 
162.002 
(51.0–447.0) 
153.03 
(53.0–524.0) 
 
< 0.001 
1–2: < 
0.001 
1–3: < 
0.001 
2–3: 
0.594 
 
Creatinine 
[mg/dL] 
 
0.73 ± 0.151  
 
0.79 ± 0.202 
 
0.77 ± 0.243 
 
0.307 
1–2: 
0.130 
1–3: 
0.328 
2–3: 
0.590 
 
AST [U/L] 
 
19.68 ± 4.111  
 
27.34 ± 
14.612 
 
23.02 ± 8.21 3 
 
0.013 
1–2: 
0.010 
1–3: 
0.987 
2–3: 
0.011 
 
ALT [U/L] 
 
23.88 ± 8.331  
 
27.34 ± 
14.612 
 
23.02 ± 8.213 
 
0.110 
1–2: 
0.112 
1–3: 
0.691 
2–3: 
0.058 
 
Haemoglobin 
 
13.95 ± 1.381 
 
13.96 ± 1.472 
 
14.35 ± 1.323 
 
0.282 
1–2: 
0.977 
1–3: 
0.158 
2–3: 
0.167 
Metrnl [pg/mL] 
(subfatin) 
20.051  
(1.56–103.78) 
(21.16 ± 17.09) 
2.622  
(1.25–
103.78) 
(5.62 ± 
14.59) 
2.013 
(0.80–19.84) 
(2.81 ± 2.85) 
 
< 0.001 
1–2: < 
0.001 
1–3: < 
0.001 
2–3: 
0.285 
Group 1 — control group; Group 2 — newly diagnosed type 2 diabetes mellitus (DM); Group 3 — long-
standing diagnosed type 2 DM; *row percentages; p* — multiple comparison p value; p** — binary 
comparison p value,  BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood 
pressure; FBG — fasting blood glucose; HbA1c — glycated haemoglobin; LDL-C — low-density 
lipoprotein cholesterol; ALT — alanine aminotransferase; AST — aspartate aminotransferase, aduration of 
newly diagnosed T2DM (months); bduration of long-standing T2DM (years). 
 
The Metrnl (subfatin) levels of the participants were as follows: control group — 20.05 (1.56–
103.78); newly diagnosed T2DM group — 2.62 (1.25–103.78); and long-standing diagnosed 
T2DM group — 2.01 (0.80–19.84) pg/mL. The Metrnl (Subfatin) levels of the participants in the 
control group were higher than in participants in the newly diagnosed T2DM and long-standing 
diagnosed T2DM groups (p < 0.001) (Fig. 1). 
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Figure 1. Comparison of subfatin levels between groups. p* — multiple comparison p value, a–b 
— comparison between control and newly diagnosed type 2 diabetes mellitus (DM); a–c — 
comparison between control and T2DM; b–c — comparison between newly diagnosed T2DM and 
T2DM; Group 1 — control group; Group 2 — newly diagnosed type 2 DM; Group 3 — long-
standing diagnosed type 2 DM 
 
Correlation analysis was performed in three studied populations. Subfatin demonstrated a negative 
correlation with insulin and HOMA-IR in the control group and long-standing diagnosed T2DM 
group, and a negative correlation with fasting glucose in the newly diagnosed T2DM and long-
standing diagnosed T2DM groups. Subfatin demonstrated a negative correlation with HbA1c in the 
long-standing diagnosed T2DM group (Tab. 2). 
 
Table 2. Correlation analysis of serum levels of subfatin (Metrnl) with anthropometric and 
biochemical data 
Variables Group 1 
(n = 50) 
Group 2 
(n = 50) 
Group 3 
(n = 50) 
Age –0.169 –0.261 0.046 
BMI   0.126 0.058 0.052 
SBP –0.008 0.096 0.227 
DBP –0.265 0.157 0.152 
FBG –0.050 –0.330* –0.374** 
Insulin –0.287* –0.252 –0.287* 
HOMA-IR –0.288* –0.254 –0.372** 
TC –0.049 0.017 0.006 
LDL-C –0.223 –0.156 0.090 
HDL-C 0.163 0.101 –0.223 
Cr –0.092 –0.122 0.222 
AST 0.149 –0.020 –0.039 
ALT 0.189 0.110 –0.094 
HbA1c –0.077 –0.177 –0.320** 
*p < 0.05; **p < 0.001; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood 
pressure; FBG — fasting blood glucose; HOMA-IR — homeostasis model assessment of insulin resistance; 
TG — triglyceride; TC — total cholesterol; LDL-C — low-density lipoprotein-cholesterol; HDL-C — 
high-density lipoprotein cholesterol; Cr — creatinine; AST — aspartate amino transferase; ALT — alanine 
amino transferase; HbA1c — glycated haemoglobin; Group 1 — control group; Group 2 — newly diagnosed 
type 2 diabetes mellitus (DM); Group 3 — long-standing diagnosed type 2 DM 
 
When the relationship between subfatin and BMI was examined without discriminating between 
groups, there was a significant negative correlation between subfatin levels and BMI (Tab. 3). 
 
Table 3. Correlation analysis between serum levels of subfatin (Metrnl) and body mass index 
(BMI) 
  BMI [kg/m2] 
 r* –.393** 
Subfatin [pg/mL] p** < 0.001 
 n 150 
r* — correlation coefficient; p** — statistical significance value 
 
Discussion 
Subfatin, is a novel adipokine that is secreted from skeletal muscle and adipose tissue, and it is 
thought to play a role in metabolic and inflammatory diseases [5]. In this context, the relationship 
between subfatin and T2DM has been the subject of current research. There have been several 
reported studies on the association between serum levels of subfatin in T2DM, but the findings are 
controversial. 
In our study, subfatin levels in the control, newly diagnosed T2DM, and long-standing diagnosed 
T2DM patient groups were 21.16 ± 17.09, 5.62 ± 14.59, and 2.81 ± 2.85 pg/mL, respectively. In 
the present study, we found that the subfatin concentration was distinctly decreased in patients 
with type 2 diabetes mellitus compared the healthy control group. Similar to the findings we 
obtained in three different studies in the literature, subfatin levels were reported to be lower in 
T2DM patients compared to the control group [9, 10, 14]. In contrast with our study, Chung et al. 
reported that the circulating levels of subfatin were increased in patients with T2DM [11]. Chung 
et al. selected the study population from the Korean sarcopenic obesity study involving patients 
with sarcopaenia and therefore may have obtained different results than our study. It has been 
shown that subfatin is secreted by skeletal muscle in humans and mice [6]. Therefore, sarcopaenia 
could be a confounding factor in the Chung et al. study, which affected the circulating levels of 
subfatin. Although the relationship between T2DM and subfatin levels is controversial, it can be 
said that subfatin levels decreased in T2DM patients based on the data we obtained and from the 
literature.  
Subfatin may play an important role in T2DM pathogenesis with its effect on insulin resistance. 
The underlying reason for investigating the relationship between subfatin and T2DM is due to the 
effect of a new molecule, subfatin, on insulin sensitivity. Studies in mice have shown that subfatin 
could increase insulin sensitivity by stimulating the peroxisome proliferator-activated receptor 
gamma (PPARg) pathway, which plays a regulatory role in insulin resistance and adipocyte 
differentiation [7]. Due to this effect of subfatin on insulin sensitivity and resistance, it is expected 
to show a negative correlation with the HOMA index. In the current study, the HOMA index of 
the control group with high subfatin level was lower than that of both diabetic patient groups. In 
similar studies in the literature comparing diabetic patients with control groups, the HOMA index 
was lower in the control group with higher subfatin levels than diabetic patients group [10–12]. 
Our data were similar to the literature and an inverse relationship was found between subfatin level 
and insulin resistance. In the correlation analysis between subfatin and HOMA index, there was a 
negative correlation in both control and diabetic patients. In the literature, two studies report a 
negative correlation between subfatin level and insulin resistance in both diabetic patients and 
control groups [14, 15]. Dadmanesh et al. reported that Metrnl was found to be correlated with 
insulin resistance and the parameter of glucose and insulin metabolism in T2DM patients, but 
Metrnl showed a negative correlation with HOMA-IR in the control; however, this correlation 
disappeared after adjusting for age and sex [9]. The common point of the literature data and the 
data we obtained is the detection of a negative correlation between HOMA index and subfatin 
levels in the diabetic patient group. 
Subfatin is expected to affect other metabolic and biochemical parameters besides insulin 
resistance. Chung et al. reported that circulating Metrnl levels in human subjects were inversely 
associated with metabolic parameters, including SBP, DBP, total cholesterol, LDL cholesterol, 
triglycerides, and fasting plasma glucose [11]. In our study, there was no statistically significant 
relationship between subfatin level and biochemical parameters. The current study failed to explain 
the relationship between subfatin levels and biochemical parameters. In future studies, the 
relationship between biochemical parameters and subfatin levels should be investigated in a larger 
population.  
Because subfatin is highly expressed in white adipose tissue, the subfatin level is expected to 
increase in those with high body mass index and waist circumference. In the current study, 
although the BMI in the diabetic patient groups was higher than in the control group, subfatin 
levels were lower than in the control group. Wang et al. reported that serum Metrnl levels were 
increased in overweight and obese subjects when compared with subjects of normal weight, and it 
was significantly correlated with BMI [7]. Löffler et al. also reported increased Metrnl expression 
in adipocytes in obese children compared with lean children [16]. Our findings contradict data 
obtained by Wang and Löffler. Fadaei et al. reported that there was a statistical relationship 
between BMI and subfatin level in diabetic patients but no statistical relationship in the control 
group [10]. According to our data and the literature, the relationship between subfatin levels and 
obesity (BMI) requires further clinical study. 
Limitations 
This study had several limitations: firstly this current study was of cross-sectional design. 
Although there was no difference between the groups in terms of age and gender, the BMI of 
diabetic patients was higher than in the control group, which may affect subfatin levels. Long-
standing diagnosed T2DM patients were selected from patients who had been treated for diabetes 
for at least five years. This observational study did not investigate the causal relationship between 
serum level subfatin and the development of T2DM. In addition, this study included only Turkish 
participants, and the findings may not apply to participants of different ethnic groups. Despite all 
our limitations, the present study included a relatively large number of subjects with 
comprehensive data on anthropometric factors, body composition, and laboratory measurements 
and thus can supplement the currently limited data about the role of subfatin in humans. 
 
Conclusion 
In our study, we compared healthy participants and diabetic patient groups, Subfatin levels were 
found to be higher in the healthy control group than in both diabetic patient groups. Subfatin level 
showed negative correlation with both insulin level and HOMA index. There was a relationship 
between subfatin and insulin resistance. Low levels of subfatin in diabetic patient groups may play 
a role in the pathogenesis of T2DM by increasing insulin resistance. Future mechanism research 
studies are required to explore the mechanism of subfatin in insulin resistance and T2DM. 
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